FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017383394> ?p ?o ?g. }

• W2017383394 endingPage "108" @default.
• W2017383394 startingPage "99" @default.
• W2017383394 abstract "A comprehensive, blinded, pathology evaluation of HER2 testing in HER2-positive/negative breast cancers was performed among three central laboratories. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) analyses were performed on 389 tumor blocks from three large adjuvant trials: N9831, BCIRG-006, and BCIRG-005. In 123 cases, multiple blocks were examined. HER2 status was defined according to FDA-approved guidelines and was independently re-assessed at each site. Discordant cases were adjudicated at an on-site, face-to-face meeting. Results across three independent pathologists were concordant by IHC in 351/381 (92 %) and FISH in 343/373 (92 %) blocks. Upon adjudication, consensus was reached on 16/30 and 18/30 of discordant IHC and FISH cases, respectively, resulting in overall concordance rates of 96 and 97 %. Among 155 HER2-negative blocks, HER2 status was confirmed in 153 (99 %). In the subset of 102 HER2-positive patients from N9831/BCIRG-006, primary blocks from discordant cases were selected, especially those with discordant test between local and central laboratories. HER2 status was confirmed in 73 (72 %) of these cases. Among 118 and 113 cases with IHC and FISH results and >1 block evaluable, block-to-block variability/heterogeneity in HER2 results was seen in 10 and 5 %, respectively. IHC−/FISH− was confirmed for 57/59 (97 %) primary blocks from N9831 (locally positive, but centrally negative); however, 5/22 (23 %) secondary blocks showed HER2 positivity. Among 53 N9831 patients with HER2-normal disease adjudicated as IHC−/FISH—(although locally positive), there was a non-statistically significant improvement in disease-free survival with concurrent trastuzumab compared to chemotherapy alone (adjusted hazard ratio 0.34; 95 % CI, 0.11–1.05; p = 0.06). There were similar agreements for IHC and FISH among pathologists (92 % each). Agreement was improved at adjudication (96 %). HER2 tumor heterogeneity appears to partially explain discordant results in cases initially tested as positive and subsequently called negative." @default.
• W2017383394 created "2016-06-24" @default.
• W2017383394 creator A5001668085 @default.
• W2017383394 creator A5013749695 @default.
• W2017383394 creator A5013971369 @default.
• W2017383394 creator A5015491002 @default.
• W2017383394 creator A5028575353 @default.
• W2017383394 creator A5029305787 @default.
• W2017383394 creator A5033033849 @default.
• W2017383394 creator A5040410256 @default.
• W2017383394 creator A5058453547 @default.
• W2017383394 creator A5060720802 @default.
• W2017383394 creator A5065306642 @default.
• W2017383394 creator A5067925193 @default.
• W2017383394 creator A5074638556 @default.
• W2017383394 creator A5082354208 @default.
• W2017383394 creator A5083189232 @default.
• W2017383394 creator A5085474533 @default.
• W2017383394 creator A5090009905 @default.
• W2017383394 creator A5090066966 @default.
• W2017383394 date "2013-02-01" @default.
• W2017383394 modified "2023-09-27" @default.
• W2017383394 title "Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)" @default.
• W2017383394 cites W1837870834 @default.
• W2017383394 cites W1867197625 @default.
• W2017383394 cites W1978956074 @default.
• W2017383394 cites W1995809615 @default.
• W2017383394 cites W2016178309 @default.
• W2017383394 cites W2034398380 @default.
• W2017383394 cites W2056769186 @default.
• W2017383394 cites W2080661875 @default.
• W2017383394 cites W2095156669 @default.
• W2017383394 cites W2098039776 @default.
• W2017383394 cites W2098775844 @default.
• W2017383394 cites W2099456677 @default.
• W2017383394 cites W2099630695 @default.
• W2017383394 cites W2101021125 @default.
• W2017383394 cites W2104558660 @default.
• W2017383394 cites W2112621891 @default.
• W2017383394 cites W2117193044 @default.
• W2017383394 cites W2124824379 @default.
• W2017383394 cites W2130900820 @default.
• W2017383394 cites W2131775652 @default.
• W2017383394 cites W2136161162 @default.
• W2017383394 cites W2138523273 @default.
• W2017383394 cites W2141393790 @default.
• W2017383394 cites W2150706560 @default.
• W2017383394 cites W2152494192 @default.
• W2017383394 cites W2154477838 @default.
• W2017383394 cites W2157719382 @default.
• W2017383394 cites W2166317024 @default.
• W2017383394 doi "https://doi.org/10.1007/s10549-013-2444-y" @default.
• W2017383394 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3585916" @default.
• W2017383394 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23420271" @default.
• W2017383394 hasPublicationYear "2013" @default.
• W2017383394 type Work @default.
• W2017383394 sameAs 2017383394 @default.
• W2017383394 citedByCount "75" @default.
• W2017383394 countsByYear W20173833942013 @default.
• W2017383394 countsByYear W20173833942014 @default.
• W2017383394 countsByYear W20173833942015 @default.
• W2017383394 countsByYear W20173833942016 @default.
• W2017383394 countsByYear W20173833942017 @default.
• W2017383394 countsByYear W20173833942018 @default.
• W2017383394 countsByYear W20173833942019 @default.
• W2017383394 countsByYear W20173833942020 @default.
• W2017383394 countsByYear W20173833942021 @default.
• W2017383394 countsByYear W20173833942022 @default.
• W2017383394 countsByYear W20173833942023 @default.
• W2017383394 crossrefType "journal-article" @default.
• W2017383394 hasAuthorship W2017383394A5001668085 @default.
• W2017383394 hasAuthorship W2017383394A5013749695 @default.
• W2017383394 hasAuthorship W2017383394A5013971369 @default.
• W2017383394 hasAuthorship W2017383394A5015491002 @default.
• W2017383394 hasAuthorship W2017383394A5028575353 @default.
• W2017383394 hasAuthorship W2017383394A5029305787 @default.
• W2017383394 hasAuthorship W2017383394A5033033849 @default.
• W2017383394 hasAuthorship W2017383394A5040410256 @default.
• W2017383394 hasAuthorship W2017383394A5058453547 @default.
• W2017383394 hasAuthorship W2017383394A5060720802 @default.
• W2017383394 hasAuthorship W2017383394A5065306642 @default.
• W2017383394 hasAuthorship W2017383394A5067925193 @default.
• W2017383394 hasAuthorship W2017383394A5074638556 @default.
• W2017383394 hasAuthorship W2017383394A5082354208 @default.
• W2017383394 hasAuthorship W2017383394A5083189232 @default.
• W2017383394 hasAuthorship W2017383394A5085474533 @default.
• W2017383394 hasAuthorship W2017383394A5090009905 @default.
• W2017383394 hasAuthorship W2017383394A5090066966 @default.
• W2017383394 hasBestOaLocation W20173833941 @default.
• W2017383394 hasConcept C104317684 @default.
• W2017383394 hasConcept C121608353 @default.
• W2017383394 hasConcept C126322002 @default.
• W2017383394 hasConcept C142724271 @default.
• W2017383394 hasConcept C143998085 @default.
• W2017383394 hasConcept C160798450 @default.
• W2017383394 hasConcept C204232928 @default.
• W2017383394 hasConcept C2777542201 @default.
• W2017383394 hasConcept C2777982462 @default.

• next